Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL TRIALS
      • AUTISM
      • INSOMNIA
      • CHRONIC PAIN
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL TRIALS
      •                 - AUTISM
      •                 - INSOMNIA
      •                 - CHRONIC PAIN
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers

By Zelira TherapeuticsAugust 20, 2020articles-2020

Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers

Sequoia Initiation Research Report, 19 August 2020
Proactive – Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics Ltd (“Zelira”) is a leading global medicinal cannabis company with access to the world's largest and fastest growing cannabis markets.

Zelira Therapeutics
5 Oct

“The boldest voices will always be heard, but the best ideas and solutions can also come in whispers.”

Zelira CEO Oludare Odumosu, continues to offer more expert advice as part of Rolling Stone magazine's invitation-only Culture Council.

Read more: http://ow.ly/xR0f50GmAQK

Twitter 1445538278581571591
Load More...

CONTACT US

    Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.